Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus

Area of Science:

• Pediatric Neurology
• Immunology
• Pharmacology

Background:

• Myasthenia gravis (MG) is a rare autoimmune disorder affecting neuromuscular junctions.
• Childhood-onset MG presents unique diagnostic and therapeutic challenges.
• Oropharyngeal MG specifically impacts swallowing and speech, significantly affecting quality of life.

Observation:

• A 2-year, 5-month-old girl with oropharyngeal MG showed limited response to standard treatments like pyridostigmine bromide, IV immunoglobulin, and high-dose prednisolone.
• Her ocular symptoms worsened despite initial immunosuppressive therapy.
• The introduction of tacrolimus at a low dose (2 mg/day) led to a dramatic improvement.

Findings:

• Tacrolimus induced complete remission of oropharyngeal myasthenia gravis symptoms.
• This remission enabled a significant reduction in the required prednisolone dosage.
• The patient experienced resolution of previously worsening ocular symptoms.

Implications:

• Tacrolimus represents a promising therapeutic option for intractable childhood-onset oropharyngeal myasthenia gravis.
• This case highlights the potential of targeted immunosuppression in managing severe pediatric autoimmune neuromuscular disorders.
• Further research into tacrolimus efficacy and safety in pediatric MG populations is warranted.